ALK and hepatocellular carcinoma: We later found this RNase1/ALK axis to be associated with immunotherapy response in mouse HCC models, in which crizotinib- or alectinib-mediated inhibition of ALK activity significantly reduced resistance to anti-PD-1 therapy.